Literature DB >> 11920465

Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma.

Toshiro Migita1, Yoshinao Oda, Seiji Naito, Masazumi Tsuneyoshi.   

Abstract

BACKGROUND: Proliferative activity in tumors depends on regulation of the cell cycle. p27(Kip1) (p27) plays a pivotal role as a negative regulator of the cell cycle. A decrease in p27 expression has been reported in many kinds of tumors, but little is known regarding p27 in patients with renal cell carcinoma (RCC).
METHODS: Expression of p27 and the related cyclins (cyclin A, cyclin E, and cyclin D1) was examined immunohistochemically in 67 patients with of clear cell RCC. The Ki-67 labeling index (MIB-1 LI) and clinicopathologic parameters related to a poor prognosis also were analyzed. To determine their prognostic significance, univariate and multivariate survival analyses were performed.
RESULTS: In tumors, there was considerable immunoreactivity for cyclin A, cyclin D1, and MIB-1, and the mean values for each were 1.08%, 16.1%, and 1.5%, respectively. Cyclin E expression was rare. The expression of p27 was correlated strongly with the expression of cyclin A (correlation coefficient, 0.432; P < 0.0004) and cyclin D1 (correlation coefficient, 0.476; P < 0.0004). Also, an inverse correlation was present between p27 expression and tumor size (P = 0.0377). In univariate analysis, the unfavorable prognostic factors were high TNM stage (P < 0.0001), large tumor size (P = 0.0016), high histologic grade (P = 0.0104), and low p27 expression (P < 0.0001). In multivariate analysis, high TNM stage (P = 0.0035) and low p27 expression (P = 0.0235) were independent prognostic factors for disease specific survival in patients with RCC.
CONCLUSIONS: The results of this study suggest that low p27 expression may be a significant and independent, unfavorable prognostic factor in patients with renal cell carcinoma. Copyright 2002 American Cancer Society. DOI 10.1002/cncr.10338

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920465

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-Hodgkin's lymphoma.

Authors:  Xiaobing Miao; Xiaohong Xu; Yaxun Wu; Xinghua Zhu; Xudong Chen; Chunsun Li; Xiaoyun Lu; Yali Chen; Yushan Liu; Jieyu Huang; Yuchan Wang; Song He
Journal:  Tumour Biol       Date:  2015-08-23

Review 2.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

3.  Targeted therapy in renal cancer.

Authors:  Tanya B Dorff; Amir Goldkorn; David I Quinn
Journal:  Ther Adv Med Oncol       Date:  2009-11       Impact factor: 8.168

4.  Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer.

Authors:  Ambrosi Pertia; David Nikoleishvili; Omar Trsintsadze; Nino Gogokhia; Laurent Managadze; Archil Chkhotua
Journal:  Int Urol Nephrol       Date:  2007-02-20       Impact factor: 2.370

5.  Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique.

Authors:  Cord Langner; Reinhard von Wasielewski; Manfred Ratschek; Peter Rehak; Richard Zigeuner
Journal:  Virchows Arch       Date:  2004-10-28       Impact factor: 4.064

6.  Immunoreactivity of p27(Kip1), cyclin D3, and Ki67 in conventional renal cell carcinoma.

Authors:  Ambrosi Pertia; David Nikoleishvili; Omar Trsintsadze; Nino Gogokhia; Laurent Managadze; Archil Chkhotua
Journal:  Int Urol Nephrol       Date:  2008-08-05       Impact factor: 2.370

7.  The expression of Cullin1 is increased in renal cell carcinoma and promotes cancer cell proliferation, migration, and invasion.

Authors:  Ji-Gen Ping; Fei Wang; Jin-Xian Pu; Ping-Fu Hou; Yan-Su Chen; Jin Bai; Jun-Nian Zheng
Journal:  Tumour Biol       Date:  2016-07-23

8.  Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma.

Authors:  Jinhee Kim; Eric Jonasch; Angela Alexander; John D Short; Shengli Cai; Sijin Wen; Dimitra Tsavachidou; Pheroze Tamboli; Bogdan A Czerniak; Kim Anh Do; Kevin J Wu; Laura A Marlow; Christopher G Wood; John A Copland; Cheryl Lyn Walker
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

9.  Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation.

Authors:  Carlos le Sage; Remco Nagel; David A Egan; Mariette Schrier; Elly Mesman; Annunziato Mangiola; Corrado Anile; Giulio Maira; Neri Mercatelli; Silvia Anna Ciafrè; Maria Giulia Farace; Reuven Agami
Journal:  EMBO J       Date:  2007-07-12       Impact factor: 11.598

10.  Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.

Authors:  Eva Juengel; Johanna Engler; Iyad Natsheh; Jon Jones; Ausra Mickuckyte; Lukasz Hudak; Dietger Jonas; Roman A Blaheta
Journal:  BMC Cancer       Date:  2009-05-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.